CNI-1493 small molecule inhibitor of IL-2 toxicities: Cytokine Networks began U.S. Phase I testing

Cytokine Networks Inc., Seattle, Wash. Product: CNI-1493 small molecule inhibitor of IL-2 toxicities Indication: Adjunct to IL-2 in cancer therapies Status: Cytokine Networks began U.S. Phase I testin...